InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
BRIEF: ImmuneOnco to raise $45 million via share placement at 13% discount
Innovative drug developer ImmuneOnco (1541.HK) announced on Thursday that it plans to place 24.2 million new shares, representing about 5.61% of its enlarged share capital, to raise HK$351 million ($45…
Obesity drug maker Sciwind targets IPO, with heavyweight backers
Supported by Tencent and Meituan, the biotech aims to launch a targeted GLP-1 drug next year that could challenge established products, but it faces stiff competition Key Takeaways: • Clinical…
A wild ride for TransThera investors: what’s the story?
The firm’s core drug has passed a minor clinical milestone, but the rally really took off when the stock was included in an array of indices tracked by passive funds…
INDUSTRY BRIEF: Trump eyes curbs on Chinese drugs, drawing industry pushback
The administration of U.S. President Donald Trump is weighing restrictions on the import of drugs and experimental therapies from China, a move that could disrupt the U.S. pharmaceutical industry and…
Zai Lab under pressure over clinical results and rival drugs
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for…
Akeso shares take a hit despite surging sales of cancer drugs
The maker of oncology drugs posted higher half-year revenues but a widening net loss and share sales by its founders have dented investor confidence Key Takeaways: Drug sales rose 49%…
Recent Articles
InnoCare licensing deal flops due to lack of upfront cash
9969.HK
688428.SHG
Zai Lab under pressure over clinical results and rival drugs
9688.HK
ZLAB.US
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
Alphamab stake sale could signal harder times ahead
9966.HK
